[Osteopontin, platelet-derived growth factor and bone morphogenetic protein-7 in children with chronic kidney disease on renal replacement therapy--preliminary results].
Cardiovascular complications are associated with CKD and tend to aggravate in the course of dialysis. The disturbed calcium-phosphate metabolism plays the crucial role in the progression of atherosclerosis. Among the new, possible factors, taking part in this process, there are the calcification inhibitors: OPN and BMP-7, and the calcification process promoter:PDGF-BB. The aim of the study was to assess the concentrations of the above mentioned factors in the dialysis patients, comparing the two types of therapy: peritoneal dialysis (PD) and hemodialysis (HD).


METHODS
OPN, PDGF-BB and BMP-7 plasma concentrations were assessed by ELISA, in 16 children on PD, in 13 on HD and in 12 controls with normal kidney function.


RESULTS
OPN concentrations were higher in HD patients, whereas in PD patients comparable to those in the control group. There were no differences between PD and HD children. PDGF-BB median values were lower in both dialysis groups than in the controls, and the lowest of them were observed in HD patients. BMP-7 concentrations were increased in dialysis patients, comparing to the control group, and higher in HD patients than in the PD ones.


CONCLUSIONS
Disturbed concentrations of OPN, PDGF-BB and BMP-7 in dialysis patients may indicate that the preventive mechanisms against the calcification disorders have been set. The fact that the changes in the concentrations of the above mentioned factors are less pronounced in the PD group, lets us assume that PD is the type of dialysis that interferes to the lesser extent with the balance between the promoters and inhibitors of calcification.
Fornalczyk
Konstancja
K
Department of Pediatric Nephrology of Medical University of Wroclaw. konif@mp.pl
Musiał
Kinga
K
Szczepańska
Maria
M
Zwolińska
Danuta
D
D000293:Adolescent; D000077214:Becaplermin; D055419:Bone Morphogenetic Protein 7 / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy*; D008297:Male; D053495:Osteopontin / Q000097:blood*; D010530:Peritoneal Dialysis; D010982:Platelet-Derived Growth Factor / Q000032:analysis*; D020574:Proto-Oncogene Proteins c-sis; D006435:Renal Dialysis; D017582:Renal Replacement Therapy
D055419:Bone Morphogenetic Protein 7; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D053495:Osteopontin; D000077214:Becaplermin